Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04761146
Other study ID # DaRT-V
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 28, 2023
Est. completion date January 1, 2026

Study information

Verified date May 2023
Source Cambridge University Hospitals NHS Foundation Trust
Contact Urology, Haematology and Medical Devices Team Clinical Trials Un
Phone 01223216083
Email cctuc@addenbrookes.nhs.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An investigation to investigate the use of diffusing alpha-emitters radiation therapy (DaRT) for the treatment of new and recurrent squamous cell carcinoma of the vulva.


Description:

Squamous cell carcinoma of the vulva is a rare cancer accounting for less than 1% of female cancers. The disease predominantly affects women over the age of 65 although the incidence in younger women is rising, a finding that has been attributed to the effect of increasing human papillomavirus (HPV) infection . The standard treatment for the primary tumour is surgical excision with the aim of achieving a 1 cm clear margin on histopathology. This requires the surgeon to remove 1.5-2 cm of surrounding normal tissue to allow for shrinkage after tissue fixation. Depending on the size and location of the tumour, the surgical procedure could vary from a wide local excision to a radical vulvectomy, including excision of adjacent structures such as the clitoris, lower urethra or anus, and/or reconstructive surgery. Wound infection and breakdown are common short-term complications of radical vulva surgery. Long term consequences include functional, cosmetic, psychological and psychosexual sequelae, which can have a significant negative impact on quality of life. Recurrence rates for vulva squamous cell carcinomas range from 15% to 33%. Local recurrence in the vulva is the most common site of relapse (70%) with the groin nodes affected in 24%, pelvic nodes in 16% and distant metastases in 19%. The treatment of choice for local recurrence is surgical excision and 5-year survival rates of up to 45% have been reported. However, patients can develop multiple recurrences over a period of time and the feasibility of surgery becomes increasingly more limited as more and more tissue is removed. Brachytherapy is a form of radiotherapy where radiation sources are placed directly in contact with or into (interstitial) cancerous tissue. The radiation emitted has a short range in tissue and the brachytherapy dose distribution conforms tightly to the location of the sources with minimal dose to the surrounding healthy tissues. Alpha Tau Medical Ltd. proposes a novel treatment for malignant tumours using intra-tumoural alpha radiation, which is delivered using the Alpha DaRT Device (Alpha DaRT applicator + Alpha DaRT seeds). The technique, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), combines the advantages of conventional interstitial brachytherapy with the destructive power of alpha particles.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date January 1, 2026
Est. primary completion date September 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Newly diagnosed or recurrent (local) vulva cancer with or without distant metastases - Histopathological confirmation of squamous cell carcinoma - Macroscopic tumour in situ (i.e. tumour not excised) - Age 18 years and over - ECOG performance status 0-2 - Life expectancy more than 6 months - Willing and able to give written informed consent to participate - Measurable target according to RECIST v1.1 - Tumour size = 7 centimetres in the longest diameter - Target is technically amenable for full coverage by the DaRT seeds Exclusion Criteria: - Non-squamous histology - Concomitant illnesses which may increase risk of radiation toxicity e.g. autoimmune diseases, vasculitis, etc. - Concomitant immunosuppressive and/or long-term corticosteroid treatment - Involvement in other studies that may affect evaluation of response or toxicity of DaRT in the past 30 days or 5 half-lives of the investigational product, whichever is longer - Pregnancy or breastfeeding - Women of child-bearing potential unwilling to use adequate contraception for the duration of the study and 6 months after completion (further details in CIP section 13) - Nodal recurrence without local recurrence - Previous diagnosis of other malignancy < 3 years of enrolment (excluding non-melanomatous skin cancer) - No concurrent chemotherapy - Patients who have received prior chemotherapy or targeted therapy require a 1-month washout before DaRT insertion - Requirement to start chemotherapy within 6 weeks of DaRT insertion

Study Design


Intervention

Radiation:
DaRT Diffusing Alpha-emitters Radiation Therapy
DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.

Locations

Country Name City State
United Kingdom Cambridge University Hospitals NHSFT Cambridge Cambridgehire

Sponsors (2)

Lead Sponsor Collaborator
CCTU- Cancer Theme Alpha Tau Medical LTD.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the feasibility of DaRT by the safety of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Measuring the feasibility of using the device by the treatment-related adverse events in the follow-up period (graded 1 'not significant' to 5 'death' with Common Terminology Criteria for Adverse Events v5.0) 6 months
Secondary Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Tumour response at 4 weeks (Day 28) after DaRT insertion as assessed by Response Evaluation Criteria in Solid Tumours (RECIST, complete response to progressive disease) criteria Day 28 (4 weeks)
Secondary To evaluate the effect DaRT on the immunological response Histological evidence of necrosis in pathological lymph nodes if removed. 4-6 weeks
Secondary Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Local control rate at 3-month and 6-month follow-up visits 6 months
Secondary Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Patient numerical rating scale (NRS) pain score, '0' representing "no pain" to '10' representing "extreme pain" 6 months
Secondary Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Patient mental state using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire. Scored 1-4 from 'Not at All' to 'Very Much' 6 months
Secondary Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Percentage of necrotic tissue if residual tumour is removed surgically 4-6 weeks
Secondary Assess the efficacy of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Patients physical state using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire. Scored 1-4 from 'Not at All' to 'Very Much' 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06048367 - Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT02997553 - Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Phase 3
Recruiting NCT06432478 - 3D Printed Custom Applicators for HDR BT (DISCO) N/A
Recruiting NCT06028724 - A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Not yet recruiting NCT06035068 - SLN Mapping and ICG Dye for Vulvar Cancer
Recruiting NCT06161428 - Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2
Completed NCT05529303 - Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients N/A
Completed NCT04147780 - Sentinel Node Extended in Squamous Cell Vulvar Cancer
Not yet recruiting NCT05761132 - Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study Phase 2